Sara Bjursten

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2026

PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.

PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.

Journal: Immunotherapy advances

Published: November 27, 2025

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.

Journal: Oncoimmunology

Published: August 08, 2025

Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.

Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.

Journal: BJC reports

Published: February 27, 2025

Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment.

Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment.

Journal: The Journal of rheumatology

Published: April 01, 2023

Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.

Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.

Journal: EBioMedicine

Published: January 30, 2023

Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint-Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor-Induced Inflammatory Arthritis.

Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint-Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor-Induced Inflammatory Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 30, 2022

Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis.

Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2021

Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma.

Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma.

Journal: The American journal of pathology

Published: February 12, 2021

Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis.

Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis.

Journal: Acta oncologica (Stockholm, Sweden)

Published: August 11, 2020

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma.

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma.

Journal: Case reports in oncology

Published: October 16, 2019

Real-world data on PD-1 inhibitor therapy in metastatic melanoma.

Real-world data on PD-1 inhibitor therapy in metastatic melanoma.

Journal: Acta oncologica (Stockholm, Sweden)

Published: June 02, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026